Dry Eye Disease Market Analysis

Dry Eye Disease Market Analysis

Based on product, the dry eye disease market is segmented as cyclosporine, topical corticosteroids, artificial tears, punctal plugs, oral omega supplements and others. The cyclosporine segment dominated the market accounting over 35% business share in 2022. Cyclosporine is an immunomodulatory medication that has been found to provide several benefits in the diagnosis and treatment of dry eye disease. Dry eye disease is often associated with chronic inflammation of the ocular surface. Cyclosporine acts as an anti-inflammatory agent by inhibiting the activity of T-lymphocytes and suppressing the release of pro-inflammatory cytokines. This helps to reduce the inflammation and improve the overall ocular surface health in dry eye disease. Cyclosporine helps to enhance tear film stability by increasing the production of aqueous tears from the lacrimal gland. This results in improved lubrication of the ocular surface and alleviation of dry eye symptoms.
 

Cyclosporine has been shown to provide significant symptom relief in patients with dry eye disease. It helps to reduce the discomfort, dryness, grittiness, and foreign body sensation commonly experienced by individuals with this condition. By addressing the underlying inflammation and promoting tear production, cyclosporine can improve the overall quality of life for patients. Cyclosporine is often used as a long-term management option for chronic dry eye disease.
 

Based on disease type, the dry eye disease market is segmented as evaporative dry eye syndrome and aqueous deficient dry eye syndrome. The evaporative dry eye syndrome segment accounted for around USD 4.7 billion in 2022. Evaporative dry eye syndrome is a type of dry eye disease characterized by a deficiency in the oily component of tears, which leads to increased tear evaporation and ocular surface dryness. Some of the major factors influencing the development of evaporative dry eye, including meibomian gland dysfunction (MGD), blepharitis, rosacea, and lid abnormalities. For instance, according to the Dry Eye Directory data, in 2022, around 1 billion people globally were suffering from meibomian gland dysfunction. These rising diseases population is anticipated to drive the demand for dry eye disease treatment across the globe.
 

Modern lifestyles, characterized by increased digital device use, prolonged screen time, and reduced blink rate, contribute to the development of evaporative dry eye syndrome. As these lifestyle factors continue to be prevalent, the incidence of evaporative dry eye syndrome is expected to rise. Evaporative dry eye syndrome becomes more common with age, primarily due to the age-related changes in the meibomian glands and the eyelid structure. As the global population continues to age, the prevalence of evaporative dry eye syndrome is projected to increase.
 

Based on distribution channel, the dry eye disease market is segmented as hospital pharmacy, retail pharmacy and online pharmacy. The hospital pharmacy segment is expected to grow at 7.0% CAGR by 2032 owing to increasing demand for devices and drugs for the diagnosis and treatment of dry eye disease. Hospital pharmacies often cater to patients with more severe or complex cases of dry eye disease who require specialized treatment. These patients may benefit from prescription medications, such as anti-inflammatory agents or immunomodulators, which are typically available in hospital pharmacies. Hospital pharmacies are equipped to provide comprehensive care to patients with dry eye disease. They offer a range of treatment options, including prescription medications, over-the-counter products, and advanced devices used for diagnosis, management, and treatment.
 

Hospital pharmacies are often conveniently located within healthcare facilities, providing easy access for patients seeking dry eye disease treatment. Additionally, availability of highly skilled healthcare professionals coupled with robust healthcare infrastructure and appropriate patient assistance for a comprehensive range of treatment options underscores the importance of hospital pharmacies thereby augmenting the market trends.
 

North America dry eye disease market was valued at USD 2.4 billion in 2022. This high market share may be ascribed to a variety of factors, including the presence of significant industry players, an increase in the number of patients suffering from dry eye disease, an expanding elderly population, among others. North America has a relatively high prevalence of dry eye disease, driven by various factors such as an aging population, widespread use of digital devices, and environmental factors. For instance, according to the American Academy of Ophthalmology data, around 20 million people in the U.S. were suffering from dry eye disease and is estimated to grow in the coming years. High demand for anti-inflammatory drugs for the diagnosis and treatment of dry eye disease in the region is anticipated to drive the market expansion.